Immediate Impact
38 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Bispecific and multispecific antibodies in oncology: opportunities and challenges
2024 Standout
Works of Wencheng Yu being referenced
Phase Ia dose escalation of IBI318, a first-in-class bispecific anti-PD-1/PD-L1, in patients with advanced tumors.
2020
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Wencheng Yu | 54 | 147 | 54 | 54 | 11 | 188 | |
| M. Karina | 119 | 178 | 40 | 62 | 12 | 274 | |
| Xuxian Chen | 62 | 206 | 136 | 75 | 14 | 262 | |
| Hiroo Yanagibashi | 77 | 96 | 44 | 78 | 17 | 212 | |
| Luca Tondulli | 109 | 170 | 63 | 104 | 14 | 278 | |
| Johan M. van Rooijen | 57 | 138 | 47 | 37 | 16 | 214 | |
| Roberto Díaz Beveridge | 36 | 87 | 31 | 30 | 11 | 126 | |
| Audrey Lardy-Cléaud | 34 | 107 | 38 | 68 | 17 | 155 | |
| Daniel López‐Trabada | 28 | 111 | 48 | 22 | 9 | 165 | |
| Ming-Ming He | 85 | 147 | 75 | 77 | 11 | 252 | |
| F. Losa Gaspà | 59 | 129 | 34 | 21 | 7 | 178 |
All Works
Login with ORCID to disown or claim papers
Loading papers...